SCID Model Market, By Model (Mouse, Pigs and Other), By Treatment (Stem Cell Therapy, Gene Therapy, and Enzyme Therapy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI478121 | Publish Date: May 2024 | No. of Pages: 180

Global SCID Model Market Companies

  • Charles River Laboratories International, Inc
  • Envigo
  • Eurofins Scientific SE
  • GenOway S.A.
  • Hera BioLabs (Transposagen Biopharmaceuticals)
  • JSR Corporation (Crown Bioscience Inc.)
  • Ozgene Pty Ltd.
  • PerkinElmer, Inc. (Horizon Discovery Group plc.)
  • Taconic Biosciences, and The Jackson Laboratory.

Recent News:

  • In November 2023, Revvity, Inc., announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. For both hereditary disorders, immediate discovery is essential to achieving a favorable result. Disease-modifying treatments are available for SMA to halt the disease's progression, and if medical attention is received in a timely manner, immunoglobulin treatments in conjunction with stem cell therapies may be able to cure a kid with SCID.